Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
230.02
+3.82 (1.69%)
At close: Jun 26, 2026, 4:00 PM EDT
228.07
-1.95 (-0.85%)
After-hours: Jun 26, 2026, 6:07 PM EDT
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,890 employees as of December 31, 2025. The number of employees increased by 90 or 3.21% compared to the previous year.
Employees
2,890
Change (1Y)
90
Growth (1Y)
3.21%
Revenue / Employee
$1,535,878
Profits / Employee
$10,191
Market Cap
14.43B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Genmab | 3,088 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
JAZZ News
- 9 days ago - Jazz Pharma, AbCellera ink antibody deal worth up to $876 million - Reuters
- 10 days ago - Jazz announces eleven presentations at SLEEP 2026 - TheFly
- 10 days ago - Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia - PRNewsWire
- 14 days ago - Jazz Pharmaceuticals lung cancer drug fails main trial goal - Reuters
- 14 days ago - Jazz Pharmaceuticals says Phase 3 LAGOON trial did not meet primary endpoint - TheFly
- 14 days ago - Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer - PRNewsWire
- 17 days ago - Jazz Pharmaceuticals price target raised to $307 from $281 at BofA - TheFly
- 17 days ago - Jazz Pharmaceuticals assumed with a Buy at Truist - TheFly